DISCOVER is the largest PrEP clinical trial, with over 5300 patients1,2
Randomized, active-controlled, double-blind trial1,3
At entry and Q12W, patients were offered1,3:
- Adherence counseling
- Prevention services (risk-reduction counseling, condoms)
Primary endpoint analysis (n=5335)1,4:
HIV incidence/100 PY when 100% of patients reached Week 48 and ≥50% reached Week 96. Secondary analysis was conducted when 100% of patients reached Week 96.
In the study population, a subset of
17%of patients were using FTC/TDF at baseline (n=897).1,5
Of these patients:
51% were randomized to DESCOVY FOR PrEP®
49% were randomized to continue using FTC/TDF
Patients selected for inclusion had significant risk of acquiring HIV1,3
a Includes mixed Black race.
b ≥6 drinks on ≥1 occasion, at least monthly.
FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; IQR=interquartile range; TGW=transgender women (who have sex with men).